Application US20200308232

CORONAVIRUSES EPITOPE-BASED VACCINES
[+] Show Details

US20200308232

1. A polypeptide comprising an amino acid sequence of at least one reconstituted Receptor Binding Motif (RBM) of a viral Spike protein or of any fragment thereof, wherein said reconstituted RBM comprises at least one linker and at least one fragment of the native RBM, said native RBM is a 30 to 200 amino acid sequence comprised within the Receptor Binding Domain (RBD) of said Spike protein forming a binding interface that interacts with the viral receptor. (5) (0)

2. The polypeptide according to claim 1, wherein said native RBM forms an extended 30 to 100 or more amino acid excursion juxtaposed along the edge of the core of the RBD and tacked to said core via a tacking segment, and wherein at least one of said linker/s replaces or is added to at least one of: said tacking segment, any part or amino acid residue/s thereof and any RBM fragment or amino acid residue/s thereof. (0)

3. The polypeptide according to claim 1, wherein said spike protein is a Coronavirus (CoV) S1 protein. (1) (0)

6. The polypeptide according to claim 1, wherein the reconstituted RBM comprises at least one linker and wherein at least one of said linker/s replaces or is added to at least one of: a loop that is said tacking segment within said RBM, any part or amino acid residue/s thereof and any RBM fragment or amino acid residue/s thereof not directly involved in receptor binding. (1) (0)

10. A composition comprising an effective amount of at least one polypeptide according to claim 1, and/or any derivative, enantiomer, fusion protein, conjugate or polyvalent dendrimer thereof, said composition further comprises at least one pharmaceutically acceptable carrier/s, excipient/s, auxiliaries, and/or diluent/s. (0)

11. An epitope based viral vaccine comprising at least one polypeptide according to claim 1, and/or any fragment thereof, any derivative, enantiomer, fusion protein, conjugate or polyvalent dendrimer thereof, said vaccine optionally further comprises at least one pharmaceutically acceptable carrier/s, excipient/s, auxiliaries, and/or diluent/s. (0)

12. A method for preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of an infection or an infectious clinical condition caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject in need thereof, the method comprising the step of administrating to said subject an effective amount of at least one polypeptide comprising an amino acid sequence of at least one reconstituted RBM of a viral Spike protein or of any fragment thereof, any derivative, enantiomer, fusion protein, conjugate or polyvalent dendrimer thereof or of any composition or vaccine comprising the same, wherein said reconstituted RBM comprises at least one linker and at least one fragment of the native RBM, said native RBM is a 30 to 200 amino acid sequence comprised within the RBD of said Spike protein forming a binding interface that interacts with the viral receptor. (1) (0)

15. A method for the preparation of a functional reconstituted RBM of a viral Spike protein, said method comprises the step of: (2) (2)

a) screening a conformer library of RBMs of said viral Spike protein with a binding molecule, wherein said library comprising plurality of bacteriophages, each expressing a reconstituted RBM comprising an amino acid sequence of at least one fragment of an RBM of a viral Spike protein and at least one exogenous combinatorial linker; and

b) identifying and producing reconstituted RBM peptides which bind at least one of said binding molecule/s.

16. The method according to claim 15, wherein said spike protein is a CoV S1 protein. (1) (0)

17. The method according to claim 16, wherein said binding molecule is at least one of: (a) the receptor for said CoV or any fragments thereof; (b) a neutralizing antibody directed against the wild type CoV RBM and any combinations thereof. (1) (0)

19. The method according to claim 15, for producing epitope based viral vaccine comprising reconstituted RBM, the method, the method further comprising the step of: (1) (1)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Application US20200308232

CORONAVIRUSES EPITOPE-BASED VACCINES

Patent Matrix® Search